Search
for
Sort by
Research 18
- Post-marketing safety profile of cladribine in multiple sclerosis: a disproportionality analysis based on the FDA adverse event reporting system
- Sweet Syndrome as the Presenting Symptom of Relapsed Hairy Cell Leukemia
- BH25 Alopecia in a patient undergoing multiple treatments for multiple sclerosis: a rare presentation and case review
- A possible solution for hair loss by inhibiting corticotropin-releasing factor (CRF) receptor from traditional Chinese medicine
- The Shifting Landscape of Disease-Modifying Therapies for Relapsing Multiple Sclerosis
- Mucocutaneous reactions to chemotherapy
- Hair and cancer chemotherapy: consequences and nursing care - a literature study
- Teriflunomide: a novel oral treatment for relapsing multiple sclerosis
- Cutaneous drug reactions
- Polarized microscopy in genetic hair disorders: case series
- Reporting on Adverse Clinical Events
- Index
- Drug-induced alopecia areata: A systematic review
- Alopecia Associated to the Use of Disease-Modifying Therapies for Multiple Sclerosis: A Scoping Review Protocol
- Poster Presentations at the 28th Joint Meeting of the International Society of Dermatopathology, March 5–6, 2025, Orlando, Florida, USA
- Selected abstracts from the 47th meeting of the Irish Endocrine Society Sligo, 24th & 25th November 2023
- Safety concerns of paternal drug exposure on fertility, pregnancy and offspring: An analysis based on the FDA adverse event reporting system
- ZALCITABINE